Trials / Completed
CompletedNCT02856425
Trial Of Pembrolizumab And Nintedanib
Phase Ib Trial Of Pembrolizumab And Nintedanib
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 196 (actual)
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Both anti-angiogenesis and anti PD1 immunotherapy have shown beneficial efficacy in solid tumors and in particular in NSCLC. Therefore it is of interest to investigate whether the combination of these two approaches is tolerable. Moreover, comprehensive pre-clinical and clinical rationale sustain the hypothesis that anti-VEGF could synergize with immunotherapy for the benefit of the patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nintedanib | Nintedanib oral tablets. An angiokinase inhibitor targeting VEGFR 1-3, FGFR 1-3, and PDGFR α/β as well as RET. Refer to current IB for product details |
| DRUG | Pembrolizumab | Pembrolizumab, Intravenous. An IgG4 anti-PD-1 blocking monoclonal antibody. Refer to current IB for product details |
Timeline
- Start date
- 2016-11-10
- Primary completion
- 2025-01-10
- Completion
- 2026-01-10
- First posted
- 2016-08-04
- Last updated
- 2026-01-20
Locations
5 sites across 1 country: France
Source: ClinicalTrials.gov record NCT02856425. Inclusion in this directory is not an endorsement.